Test shorter blood-thinner use versus standard after heart attack
Part of Heart & circulation clinical trials.
This trial compares two ways of using anti-platelet (blood-thinner) medicines after a specific kind of heart attack (STEMI) treated with a stent. It aims to see if switching sooner to one medicine (instead of two for longer) works just as well and may reduce risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a STEMI heart attack and are scheduled for stent treatment (PCI)
- Your ECG showed specific heart attack signs, or you had a new/likely new left bundle branch block
- If you had more than one blockage, they treated only the “culprit” blockage during the first procedure
- At 30–45 days, you must have taken both blood thinners exactly as prescribed with no major problems
- Your stent procedure must have successfully opened the target areas (residual narrowing under 30%) and, if needed, other important blockages were fully treated within 15 days
- You must be able to take aspirin and a P2Y12 tablet (like prasugrel) and have safe blood counts (platelets not too low, hemoglobin not too low)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is comparing two durations of antiplatelet therapy (blood thinners) after getting a heart stent, using ultrasound guidance to tailor the treatment. The goal is to find a shorter, safer medication plan that still prevents blood clots and heart attacks.
This trial looks at whether using heart imaging (OCT or angiogram) to guide how long you take two blood thinners after a heart attack (STEMI) can be safe and effective. If you qualify, your doctor may be able to reduce your blood thinner use sooner, which could lower bleeding risk while still protecting your heart.
This trial tests if a lower dose of prasugrel, taken alone (without aspirin), is safe and works well for people who have had a stent placed for chest pain or a heart attack. It might be an option for those who need to simplify their medication routine.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
This trial studies whether a specific stent (with no polymer coating) plus a single blood thinner plan with aspirin and another P2Y12 medicine is as safe and effective as the standard two-medicine plan after a STEMI heart attack. It may help people avoid longer exposure to stronger blood-thinning if the new approach works as well.
This study tests whether a shorter course of blood-thinning medication after heart stent placement is safer and just as effective for older adults. It aims to reduce bleeding risks while still preventing heart attacks and strokes.
Hear when a new Dual Antiplatelet Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.